Abstract
Hip pain is a common musculoskeletal complaint that leads many people to seek medical attention. Approximately 14.3% of the population aged 60 and above have reported substantial hip pain persisting for most days over a six-week period. Our research aimed to identify the genetic variants associated with hip pain by conducting a genome-wide association study (GWAS) on the hip pain phenotype, utilizing data from 221,127 participants from the UK Biobank cohort. We found 7 different loci associated with hip pain, with the most significant SNP being rs77641763, which is situated within the EXD3 gene (p value = 2.20 x 10-13). We utilized publicly available summary statistics from a previous GWAS meta-analysis on hip osteoarthritis as a replication cohort. Two loci (rs12042579 and rs9597759) were suggestively replicated. Further analysis of tissue expression revealed significant associations between brain tissues and hip pain. Additionally, we found strong genetic correlations between hip pain and other pain phenotypes. This research has therefore identified multiple genetic loci associated with hip pain, which may potentially pave the way for medical interventions that can alleviate the burden of hip pain.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Pioneer and Leading Goose R&D Program of Zhejiang Province 2023 with reference number 2023C04049 and Ningbo International Collaboration Program 2023 with reference number 2023H025. This work was also supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No 633491 (DOLORisk).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The dataset we used was approved by the UK Biobank with a project number 89386. The ethics of this UK Biobank project was approved by the ethical committee of the University of Nottingham Ningbo China.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript All data produced are available upon request
